Solifenacin treatment in men with overactive bladder: effects on symptoms and patient-reported outcomes

References

• Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167–178.
   PubMed Web of Science ®Google Scholar
• Abrams P, Artibani W, Cardozo L, Dmochowski R, van Kerrebroeck P, Sand P. Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn 2006;25:293.
   PubMed Web of Science ®Google Scholar
• Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 2006;49:651–659.
   PubMed Web of Science ®Google Scholar
• Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50:1306–1315.
   PubMed Web of Science ®Google Scholar
• Miner MM. Primary care physician versus urologist: how does their medical management of LUTS associated with BPH differ? Curr Urol Rep 2009;10:254–260.
   Google Scholar
• Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008;54:543–562.
   PubMed Web of Science ®Google Scholar
• Khullar V, Chapple C, Gabriel Z, Dooley JA. The effects of antimuscarinics on health-related quality of life in overactive bladder: a systematic review and meta-analysis. Urology 2006;68(2 Suppl):38–48.
   Google Scholar
• Novara G, Galfano A, Ficarra V, Artibani W. Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: a systematic review. Eur Urol 2006;50:675–683.
   PubMed Web of Science ®Google Scholar
• Kaplan SA. New data on tolterodine: do recent findings dispel questions about treating overactive bladder in men? Eur Urol Suppl 2007;6:10–16.
   Google Scholar
• Garely AD, Kaufman JM, Sand PK, Smith N, Masakazu A. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare open-label trial (VOLT). Clin Ther 2006;28:1935–1946.
   PubMed Web of Science ®Google Scholar
• Chancellor MB, Zinner N, Whitmore K, Kobashi K, Snyder JA, Siami P, Karram M, Laramee C, Capo JP, Jr., Seifeldin R, Forero-Schwanhaeuser S, Nandy I. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study. Clin Ther 2008;30:1766–1781.
   PubMed Web of Science ®Google Scholar
• Coyne KS, Matza LS, Kopp Z, Abrams P. The validation of the Patient Perception of Bladder Condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 2006;49:1079–1086.
   PubMed Web of Science ®Google Scholar
• Coyne K, Revicki D, Hunt T, Corey R, Stewart W, Bentkover J, Kurth H, Abrams P. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 2002;11:563–574.
   PubMed Web of Science ®Google Scholar
• Coyne KS, Matza LS, Thompson CL, Kopp ZS, Khullar V. Determining the importance of change in the Overactive Bladder Questionnaire. J Urol 2006;176:627–632; discussion 632.
   PubMed Web of Science ®Google Scholar
• Rovner ES, Kreder K, Sussman DO, Kaplan SA, Carlsson M, Bavendam T, Guan Z. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. J Urol 2008;180:1034–1041.
   PubMed Web of Science ®Google Scholar
• Ronchi P, Gravina GL, Galatioto GP, Costa AM, Martella O, Vicentini C. Urodynamic parameters after solifenacin treatment in men with overactive bladder symptoms and detrusor underactivity. Neurourol Urodyn 2008;28:52–57.
   Google Scholar
• Karram MM, Toglia MR, Serels SR, Andoh M, Fakhoury A, Forero-Schwanhaeuser S. Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology 2009;73:14–18.
   PubMed Web of Science ®Google Scholar
• Dmochowski R, Abrams P, Marschall-Kehrel D, Wang JT, Guan Z. Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder. Eur Urol 2007;51:1054–1064.
   PubMed Web of Science ®Google Scholar
• Kaplan SA, Roehrborn CG, Dmochowski R, Rovner ES, Wang JT, Guan Z. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology 2006;68:328–332.
   PubMed Web of Science ®Google Scholar
• Gallegos PJ, Frazee LA. Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia. Pharmacotherapy 2008;28:356–365.
   Google Scholar
• Kaplan SA, Walmsley K, Te AE. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 2005;174:2273–2275.
   PubMed Web of Science ®Google Scholar
• Abrams P, Kaplan S, De Koning Gans HJ, Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006;175(3 Part 1):999–1004.
   Google Scholar
• Dahm TL, Ostri P, Kristensen JK, Walter S, Frimodt-Moller C, Rasmussen RB, Nohr M, Alexander N. Flavoxate treatment of micturition disorders accompanying benign prostatic hypertrophy: a double-blind placebo-controlled multicenter investigation. Urol Int 1995;55:205–208.
   Google Scholar
• Kershen RT. Algorithms for the management of overactive bladder. Curr Urol Rep 2009;10:352–361.
   Google Scholar
• Lee SE, Chung JS, Han BK, Moon KH, Hwang SI, Lee HJ, Choe G, Hong SK. Relationship of prostate-specific antigen and prostate volume in Korean men with biopsy-proven benign prostatic hyperplasia. Urology 2008;71:395–398.
   Web of Science ®Google Scholar
• Mao Q, Zheng X, Wang Y, Qin J, Yang K, Bai Y, Xie L. Relationships between total/free prostate-specific antigen and prostate volume in Chinese men with biopsy-proven benign prostatic hyperplasia. Int Urol Neph 2009 Feb 18 [Epub ahead of print].
   Google Scholar
• Roehrborn CG, Kaplan SA, Kraus SR, Wang JT, Bavendam T, Guan Z. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. Urology 2008;72:1061–1067.
   PubMedGoogle Scholar
• Roehrborn CG, Kaplan SA, Jones JS, Wang JT, Bavendam T, Guan Z. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. Eur Urol 2009;55:472–479.
   PubMed Web of Science ®Google Scholar
• MacDiarmid S, Rogers A. Male overactive bladder: the role of urodynamics and anticholinergics. Curr Urol Rep 2007;8:66–73.
   Google Scholar